# Caffeine for Excessive Daytime Somnolence in Parkinson's Disease

> **NCT00459420** · PHASE2,PHASE3 · COMPLETED · sponsor: **Ron Postuma** · enrollment: 58 (actual)

## Conditions studied

- Parkinson's Disease
- Excessive Daytime Somnolence

## Interventions

- **DRUG:** Caffeine 100-200 mg BID
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00459420
- **Lead sponsor:** Ron Postuma
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2015-04-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00459420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00459420, "Caffeine for Excessive Daytime Somnolence in Parkinson's Disease". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00459420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*